| This week's sponsor is Premier Research. | | | Clearing the Path for Orphan Drug Development
The unmet therapeutic need in rare disease is huge, but so are the cost and complexity of drug development. Read our white paper to see how the FDA and EMA are easing the path to regulatory approval. Premier Research. It's what we do. Best. |
Top Stories Tuesday, December 6, 2016 After a torrid year that has seen multiple deaths in testing, FDA- and self-imposed study halts and its shares tanking, Juno last night held up to the light its new great hope: JCAR017 Tuesday, December 6, 2016 AbbVie has struck five-year cancer research pacts with Johns Hopkins University School of Medicine and Northwestern University's Lurie Cancer Center. The similarly-structured agreements give the academic centers access to new AbbVie therapies for use in preclinical research—and give the drug developer an option to license discoveries made by its new partners. Tuesday, December 6, 2016 TiGenix has taken another step toward its delayed Nasdaq IPO. The stem cell therapy specialist is aiming to net $42.9 million (€39.8 million) through the listing, approximately half of which will go toward a U.S. late-phase trial of Crohn's disease candidate Cx601. Tuesday, December 6, 2016 Creo Medical Group is set to raise approximately $26 million in an IPO. The British surgical endoscopy specialist will use the money to commercialize its radiofrequency and microwave-enabled system for tissue dissection, resection, ablation and coagulation in the U.S. and Europe. Monday, December 5, 2016 Johnson & Johnson’s interest in Actelion as a takeover target may not yet have sparked a deal, but it has made founder and CEO Jean-Paul Clozel a billionaire. Thing is, Clozel isn't nearly as excited about making a deal as his investors are. | | | AstraZeneca has posted some early data for its med acalabrutinib in chronic lymphocytic leukemia. Release Sage has sped up its plans for SAGE-547 in postpartum depression after talking with the FDA. Statement Auris Medical said it is "on track" to restart enrollment for its Keyzilen tinnitus program after a chat with regulators. Release | |
|
Resources Presented By: Lenovo Get the stats you need to start down the path to a more secure infrastructure, today. Presented By: Lenovo What's the first step to a better patient experience? The patient experience starts well before the exam room or even reception - it begins as soon as your patients pull into the parking structure. Presented by: DocuSign DocuSign’s eSignature solutions modernize healthcare and life science organizations by eliminating paper and antiquated signature processes while meeting compliance requirements and reducing costs and errors. Presented by: DocuSign The patients who rely on your scientific leadership are expecting more. Presented by: DocuSign The U.S. Department of Justice has collected upwards of $17 billion in settlements from the healthcare industry since 2009, including more than $2 billion from a single life sciences company. Sponsored By: Salesforce Life sciences companies, like many industries today, face new challenges across the board. Read More. Presented By: ISR Reports Make essential outsourced bioprocessing decisions by staying informed of industry outsourcing practices and contract manufacturer usage patterns with ISR’s Bioprocessing Services and Technologies Market Trends and Outsourcing Dynamics report. Presented By: ISR Reports ISR’s Biosimilars in the US Oncology Market (2nd Edition) report provides data and insights from 101 US-based, board-certified oncologists/hematologist oncologists as to their expectations, fears, and aspirations for biosimilars in oncology. Presented By: ISR Reports Pinpoint the information oncologists find most valuable and the best sales channels for delivering specific types of data/information. Presented By: ISR Reports ISR’s Bioprocessing Market Trends and Outsourcing Dynamics: 2016-2021 report provides an overview of the current market dynamics for bioprocessing as well as an outlook on what the marketplace will look like in five years. Presented By: ISR Reports ISR’s CRO Quality Benchmarking – Phase II/III Service Providers (8th Edition) report provides a Consumer Reports-style analysis of Phase II/III CRO service quality from hundreds of users who rated 44 Phase II/III CROs across 26 critical dimensions of quality. Presented by: Patheon Can you avoid a risky trial-and-error approach to find the right path for your poorly soluble molecule by utilizing a CDMO? Download this complimentary Whitepaper to learn more! Presented by: Biotech Primer This 3-part webinar series is specifically geared toward the non-science professional who needs to better understand industry terminology, science, techniques and issues. Sponsored by: Veeva Systems Gartner research on short- and long-term strategies for IDMP compliance. FierceBiotech Executive Breakfast: Deciphering Immuno-Oncology, Trends in Deal-Making and R&D January 10, 2017 | San Francisco, CA Precision LBx Summit: Translating Next Generation Liquid Biopsies into Clinical Reality January 30-February 1, 2017 | San Diego, CA DeviceTalks December 12, 2016 | Newport Beach, CA 24th International Molecular Medicine Tri-Conference February 19-24, 2017 | Moscone North Convention Center | San Francisco, CA CBI’s IISR 2017 Summit February 14-15, 2017 | Philadelphia, PA | 